Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus

Abstract

BackgroundAnimal studies have demonstrated that an inhibition of DPP-4 has an impact on the secretion of cholesterol and apoB by the small intestine. However, there is no consensus about the changes of the lipid profile following administration of sitagliptin.MethodsAccordingly, we treated patients who had type 2 diabetes complicated by dyslipidemia with sitagliptin and evaluated its effects on the profile of lipid parameters. A total of 248 outpatients with type 2 diabetes complicated by dyslipidemia were treated with sitagliptin at a daily dose of 50 mg. The levels and percent changes of lipid and glucose metabolism markers were measured at baseline and at 12 weeks after the initiation of treatment.ResultsBoth plasma glucose and HbA1c were significantly decreased. Among the lipid parameters, total cholesterol (TC) and non-high-density lipoprotein cholesterol (non-HDL-C) showed a significant decrease (TC 3.6±15.6%, non-HDL-C 2.9±19.7%; P < 0.05). Stratified analysis revealed a significant decrease of TC, low-density lipoprotein cholesterol (LDL-C) and non-HDL-C in the high triglyceride (TG) group (≥ 150 mg/dL) (P < 0.05). Analysis stratified by demographic factors demonstrated significant differences in the changes of TC, LDL-C and non-HDL-C. Multivariate analysis showed a significant decrease of the TC, LDL-C and non-HDL-C levels in the high TG group (≥ 150 mg/dL), as well as a significant decrease of TC and LDL-C in patients using strong statins.ConclusionsThe results suggested that sitagliptin caused a significant decrease of TC, LDL-C and non-HDL-C, particularly in patients with high baseline TG levels and those using strong statins.

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

“…In the present study, sitagliptin did not cause any increase in the body mass index. Sitagliptin also decreases postprandial triglyceride level [27] and lowers blood pressure, blood lipid level [28] and alkaline phosphatase level [29]. Our present study also showed decreased systolic and diastolic blood pressures, decreased LDL-C level and decreased triglyceride levels, which is similar to results from previously published studies.…”

Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport

“…In addition to their effect of improving glycemic control, DPP‐4 inhibitors have recently also been reported to exert extrapancreatic actions, including ameliorating the risk of diabetic complications, such as nephropathy, retinopathy and neuropathy, and also the risk of cardiovascular disease. Several previously published studies, including a meta‐analysis, have also reported the lipid‐lowering effect of DPP‐4 inhibitors. Two meta‐analyses have shown that DPP‐4 inhibitors, such as sitagliptin, vildagliptin, alogliptin, saxagliptin and linagliptin, reduce both the serum cholesterol and serum triglyceride levels.…”

A CROSS SECTIONAL STUDY IN NORTH EASTERN UTTAR PRADESH POPULATION FOR THE ESTIMATION OF BMI, HDL & TRIGLYCERIDES LEVELS IN RECENTLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS TAKING METFORMIN ALONE, METFORMIN WITH ADD ON SITAGLIPTIN AND SITAGLIPTIN ALONE.

“…[10] had revealed changes of the lipid profile after Sitagliptin treatment, the HDL level & Triglyceride level were not significantly (p>0.05) reduced after 12 weeks of Sitagliptin treatment from baseline.…”